Horizon Tech Finance Extends $15M Credit Line to Bioness Medical
Event summary
- Horizon Technology Finance provided a $15M senior credit facility to Bioness Medical, with $10M funded at closing and $5M available for future growth.
- Bioness develops FDA-approved neurorehabilitation technologies for stroke and spinal cord injury recovery.
- The deal reflects Horizon’s focus on venture lending for healthcare and life sciences companies.
- Bioness is backed by Accelmed Partners and operates in hospital, outpatient, and home-based care settings.
The big picture
Horizon’s $15M loan to Bioness underscores the growing demand for flexible growth capital in the healthcare technology sector. The deal aligns with Horizon’s strategy of supporting innovative, clinically validated companies with strong market positions. As the neurorehabilitation market expands, such financing arrangements are likely to become more common, reflecting broader trends in private credit markets.
What we're watching
- Execution Risk
- Whether Bioness can deploy the capital effectively to expand its product portfolio and global reach.
- Market Position
- How this financing strengthens Bioness’s competitive edge in the neurorehabilitation market.
- Industry Trends
- The pace at which venture debt financing accelerates in the healthcare technology sector.
Related topics